ERNA Stock Analysis: Buy, Sell, or Hold?
ERNA - Ernexa Therapeutics Inc. Common Stock
$4.87
0.35 (7.74%)
â˛
5d:
+14.05%
30d:
+22.06%
90d:
-60.91%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ERNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ERNA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ERNA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ERNA is currently trading at $4.87, which is considered fair relative to its 30-day fair value range of $3.60 to $5.50.
Technical Outlook: Technically, ERNA is in a uptrend. Immediate support is located at $4.02, while resistance sits at $5.20. The stock is showing strong short-term momentum, up 7.7% recently.
Market Sentiment: ERNA scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+563.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ERNA is in a uptrend. Immediate support is located at $4.02, while resistance sits at $5.20. The stock is showing strong short-term momentum, up 7.7% recently.
Market Sentiment: ERNA scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+563.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.60 -
$5.50
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.7%)
- BULLISH: Trading 563.7% below Wall St target ($30.00)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.60 -
$5.50
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.02
Resistance Level
$5.20
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.43
Wall Street Target
$30.00
(+563.7%)
Revenue Growth (YoY)
-94.1%
Share & Embed Analysis
Last updated: August 21, 2026 2:34 PM ET
Data refreshes hourly during market hours. Next update: 3:34 PM
Data refreshes hourly during market hours. Next update: 3:34 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ERNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 38 SELL |
